COMP <GO>
MIRM vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
Mirum Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MIRM 4
— UNH 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
LAST: $85.74 (+0.87%) • MKT CAP: $5.57B
roic
-3.90%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
roic
12.38%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRM | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -3.90% | 12.38% | -16.28 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.98% | 6.25% | -5.27 | UNH | /fcf-yield <GO> |
| Operating Margin | -4.20% | 5.32% | -9.52 | UNH | /operating-margins <GO> |
| Net Profit Margin | -4.50% | 3.53% | -8.03 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 54.70% | 3.33% | +51.37 | MIRM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.29 | 3.09 | +3.20 | MIRM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | MIRM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.2 | 55.1 | -4.90 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.33 | +0.66 | MIRM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 17.7x | +14.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.57B | $359.43B | -$353.87B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRM REV | UNH REV | MIRM GROSS % | UNH GROSS % | MIRM FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | $447.57B | — | 88.7% | $54.9M | $16.07B |
| FY 2024 | $336.9M | $400.28B | — | 88.3% | $9.3M | $20.70B |
| FY 2023 | $186.4M | $371.62B | — | 89.6% | -$79.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
UNH // BETA 0.33